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Al Kindi et al Evolving Technology/Basic Scienceminimizing the hemodynamic side effects. Future studies
are needed to optimize the encapsulation and milrinone
release in a predictable manner. In addition, using PLGA-
MP technology could potentially develop different
sustained-release milrinone formulations, such as an intra-
muscular, a subcutaneous, or an oral form that can be deliv-
ered by various routes. Inhaled milrinone-PLGA-MPs is
one such example that sustained milrinone delivery can
be achieved by nasal administration with minimal systemic
side effects and toxicity. The application of MNPs in drug
delivery has proved to be effective and feasible. Additional
exploitation for cardiovascular application could hold great
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Dr Vivek Rao (Toronto, Ontario, Canada). Thank you. I have
no conflicts to disclose.
I would like to congratulate you on a very clear presentation and
a very interesting technological proof-of-concept study. You found
that the encapsulation of milrinone in these MPs led to a sustained
release of milrinone with potential beneficial effects.
I have 3 questions for you related to this study. The first is the
PLGA that you used for the MPs appears to me to be lipophilic.
In your in vitro release studies, you had phosphate-buffered saline.
Have you done studies in which you actually have a mono layer of
cells to determine whether the cells tend to accumulate this
particle?
Dr Al Kindi. PLGA polymer is hydrophobic, but it can
encapsulate the hydrophilic drugs by mechanical entrapment
inside its highly porous meshlike structure. That is the idea of
how this PLGA can release milrinone in a sustained way because
it is lipophilic, so the release will be slowly over 24 hours.
Dr Rao. But can be it absorbed into a cell wall and have..
Dr Al Kindi. Actually, the degradation of the PLGA in humans
is by hydrolysis. So, the end result is lactic acid, and the lactic acid
will be absorbed by the liver, and then that is how it is metabolized.
That is why it is biodegradable and approved by the Food and Drug
Administration.diovascular Surgery c Volume 148, Number 5 2323




SDr Rao. My second question relates to the hemodynamic ef-
fects of both drug delivery systems. You mentioned that one of
the limitations was a lack of invasive hemodynamic assessments.
In the report, you documented that the heart rate and blood pres-
sure did not differ among the 3 groups.
How do you reconcile that intravenous injection of milrinone
did not cause tachycardia or a hypotensive effect, which is
commonly seen clinically?
Dr Al Kindi. That is an excellent question. The way we
measured the blood pressure and heart rate was a noninvasive
method using a tail cuff. It is noninvasive method and can be
affected by body temperature. We did not see any difference in
the heart rate and blood pressure among all 3 groups. Probably,
in future studies, we should measure the heart rate and blood pres-
sure more precisely, using invasive methods.
DrRao. Finally, in your conclusion, as well as in your last slide,
you tease us with the concept of using this alternative delivery
technique. So, do you have any preliminary data that you can share
with us in terms of prolonging the effect of milrinone therapy using
subcutaneous, intramuscular, or inhalational therapy?
Dr Al Kindi. Actually, the size of the MPs we used in this proj-
ect was 4 mm, which is ideal actually for the inhalation route.
That would also be a very good method to deliver milrinone and
to decrease its systemic side effects, so that is why we are thinking
along that line.
Dr David H. Harpole, Jr (Durham, NC). Excellent study, very
interesting. I wanted to have you give us a little of your insight. We
know that milrinone is truly an inotropic agent in the heart. It also,
as you mentioned in the very beginning, has vasodilatory effects in2324 The Journal of Thoracic and Cardiovascular Surthe pulmonary circulation, it unloads the right heart. Actually, a
number of investigators think that might be how it is more cardio-
protective, because it actually unloads the heart.
Now, your microspheres were large enough that they probably
would not be absorbed directly into the pulmonary circuit. You
just mentioned this. If you changed your delivery system to inhaled
with a slightly smaller particle, do you think youmight also receive
the benefit of the pulmonary unloading, which would help the right
heart in failure?
Dr Al Kindi. It all depends on your treatment target. If your
target is pulmonary hypertension, I think the inhalation method
would be appropriate in this context.
If you are treating heart failure or you want to have the systemic
effect of milrinone, perhaps the subcutaneous route or intramus-
cular route would be ideal. It all depends on your target.
Dr Todd K. Rosengart (Houston, Tex). It would appear that
what you are showing us is that you can extend the duration of
the effect from about 3 hours to 12 hours or so; however, perhaps
what is more exciting about this, as you alluded, is that nanopar-
ticles will allow the use of inhalation instead of the current
formulation.
So, is this a change in the method of delivery or is the impor-
tance of your study the duration of effect, or is it something else?
Dr Al Kindi. This study is the first study to use MPs to deliver
cardioactive drugs. So, we have to start with the intravenous route.
However, ultimately we are working on delivering these MPs us-
ing a more convenient method. As I mentioned, we will start
with the subcutaneous route and then to more difficult routes,
such as the inhalation route, and that is our ultimate goal.gery c November 2014
